title: [Use of mesenchymal stem cells in the combination therapy of ulcerative colitis].
abstract: OBJECTIVE
  To compare results of treatment in patients with moderate and severe ulcerative colitis (UC), receiving standart anti-inflammatory therapy (second group) and its combination with bone marrow-derived mesenchymal stromal cells (MSC) (first group).
  
  
  RESULTS
  Complex therapy of UC acute flare-up, including MSC did not influence on reccurence frequency, remission duration and mean value of clinical and endoscopic activity indices during 1 year of follow-up: in 1 group UC flare-up occurred in 2 (16.7%) patients, in 2 group--in 3 patients (30%). RR was 0.3 (95% CI 0/08--1.36; p=0.2; x2=1.47). After 2 years of follow-up risk of UC exacerbation in 1 group was 3 times lower than in the 2 group (p=0.03). Mean duration of remission in the 1 group was 22 months, in the 2 group--17 months (p=0.049). After 3 years of follow-up remission duration in the 1 and 2 groups were 22 and 22 months, respectively (p=0.66). Activity Index according to Rachmilevich in the 1 group was 4.75+/-1.13 points, in the 2--8.1+/-1.1 points (p=0.001).
  
  
  CONCLUSIONS
  MSC application increases efficacy of anti-inflammatory treatment in patients with acute exacerbation of UC.
authors.affiliation: Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.
authors.forename: O V
authors.initials: OV
authors.lastname: Knyazev
authors.affiliation: Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.
authors.forename: A I
authors.initials: AI
authors.lastname: Parfenov
authors.affiliation: A.F. Tsyb Medical Radiology Research Center, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Obninsk, Russia.
authors.forename: A G
authors.initials: AG
authors.lastname: Konoplyannikov
authors.affiliation: Moscow Clinical Research and Practical Center, Moscow Healthcare Department, Moscow, Russia.
authors.forename: O N
authors.initials: ON
authors.lastname: Boldyreva
mesh_terms: D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D003093:Colitis, Ulcerative / Q000175:diagnosis / Q000503:physiopathology / Q000628:therapy; D003113:Colonoscopy / Q000379:methods; D003131:Combined Modality Therapy / Q000379:methods; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage*; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D008875:Middle Aged; D012074:Remission Induction / Q000379:methods; D012426:Russia; D012720:Severity of Illness Index; D014182:Transplantation, Autologous; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D019804:Mesalamine